



## 2/25




3 / 25




021720-001310US, 10/773,767 Kent J. Tobin, Reg. No. 39,496 Telephone: 650-326-2400 Title: Drug Model Explorer Inventors: Jacob W. Mandema et al. Sheets of drawings 4 of 25






5 / 25







021720-001310US, 10/773,767 Kent J. Tobin, Reg. No. 39,496 Telephone: 650-326-2400 Title: Drug Model Explorer Inventors: Jacob W. Mandema et al. Sheets of drawings 7 of 25

7/25







FIG. 7B








021720-001310US, 10/773,767 Kent J. Tobin, Reg. No. 39,496 Telephone: 650-326-2400 Title: Drug Model Explorer Inventors: Jacob W. Mandema et al. Sheets of drawings 10 of 25

10 / 25



IG. 7E









FIG. 7F













 $\dot{+}$ 

021720-001310US, 10/773,767 Kent J. Tobin, Reg. No. 39,496 Telephone: 650-326-2400 Title: Drug Model Explorer Inventors: Jacob W. Mandema et al. Sheets of drawings 15 of 25

15 / 25










021720-001310US, 10/773,767 Kent J. Tobin, Reg. No. 39,496
Telephone: 650-326-2400
Title: Drug Model Explorer
Inventors: Jacob W. Mandema et al.
Sheets of drawings 17 of 25

17 / 25








19 / 25

Settings.. ☐ Ranges: Treatment
Drug 1: 0.0 mg
Drug 1: 20.0 mg Treatment Drug 1: 0.0 mg Drug 1: 20.0 mg Percent Patients to E1 Target vs Drug A
Base E1: 2.5-5
Target E1: <1
Ref. Drug 2: 5.0 mg + Drug B: 2.5 mg ☑ Overlay E1 % change vs Drug A Ref. Drug 2: 5.0 mg + Drug B: 2.5 mg 30 Drug A (mg) Update View 2 Plots Ş١ ٥٢ Percent Patients to E2
 Target
 Percent Patients with AE
 Percent Relative Risk 0 0 10 20 0ther Target E2 Drug B (mg) ☑ Drug A (mg) Class ABC Base E2 Back Forward | Model Documentation File Edit Select View Plot Help 0 01.2502.5 0 10 020 Other ☑ E1 % change ☑ Percent Patients to E1 Target 0.75 0.75 0.75 0.75 0.75 Target E1 E2 % change ✓ Drug 1 (mg) Pharsight DMX Drug 2 (mg) None Half
Half
Full 1-2.5 2-5.5 1-2.5 1-2.5 1-1.5 10-15 10-09. Class 123 Endpoints — Base E1 Treatment Population Reference Ready

021720-001310US, 10/773,767 Kent J. Tobin, Reg. No. 39,496 Telephone: 650-326-2400 Title: Drug Model Explorer Inventors: Jacob W. Mandema et al. Sheets of drawings 20 of 25

20 / 25

FIG. 7N



021720-001310US, 10/773,767 Kent J. Tobin, Reg. No. 39,496 Telephone: 650-326-2400 Title: Drug Model Explorer Inventors: Jacob W. Mandema et al. Sheets of drawings 21 of 25

21 / 25




FIG. 8

22 / 25





FIG. 8A



24 / 25




FIG. 10A

T

25 / 25

